What did @hacksmithsbackup actually say?
The creator's core argument is that BPC-157's cancer risk is "somewhat unwarranted" because there's no clinical data showing it causes cancer, and the concern is purely hypothetical. To their credit, they do tell people actively in treatment or in remission to avoid it, and they recommend speaking with a doctor. That's more nuance than most peptide content on TikTok.
The mechanism they're referencing is real: BPC-157 promotes angiogenesis, meaning it encourages the growth of new blood vessels. Their analogy to sugar and glutamine feeding cancer cells is meant to minimize the concern by saying plenty of things do this. That framing, while not entirely wrong, sidesteps something important about how angiogenesis specifically interacts with tumor biology, which we'll get into.
Does the science back this up?
Partially, but the creator is selectively accurate in a way that could give people false confidence. They're right that there are no completed human clinical trials linking BPC-157 to cancer initiation. But the angiogenesis concern is not just theoretical noise.
BPC-157 has been shown in animal studies to upregulate VEGF (vascular endothelial growth factor) signaling pathways. VEGF is one of the primary drivers of tumor angiogenesis, meaning it helps existing tumors recruit new blood vessels to sustain growth. Sikiric et al. (2018, Current Pharmaceutical Design) documented BPC-157's effects on VEGF and related pathways in rodent models. Comparing this to eating sugar is not a fair equivalence. Sugar doesn't selectively stimulate the same signaling cascades that tumors exploit to grow and metastasize. The mechanisms are categorically different.
That said, the creator is correct that no human study has demonstrated BPC-157 causing cancer de novo. The absence of that data is real, though largely because human trials on BPC-157 barely exist at all, not because researchers looked and found no signal.
What did they get wrong (or right)?
They got the absence-of-evidence framing wrong. Saying "there is no clinical data" sounds reassuring, but BPC-157 has almost no large-scale human trial data on anything, not just cancer. The lack of evidence for harm is not the same as evidence of safety. That distinction matters enormously when you're talking to people who may be in treatment or recently in remission.
The anecdote about people using it while "actively battling the big C" with "no changes in terms of growth or spread" is the most problematic part of the caption. N-of-a-few observations with no controls, no imaging data, and no blinding are not evidence. Cancer progression is complex and variable. Attributing stability to BPC-157 use, or its absence of harm, from informal observation is not a scientific argument.
What they got right: the recommendation to avoid BPC-157 if you have active cancer or are recently in remission is appropriate. The call to consult a medical professional before use is appropriate. Those aren't just legal disclaimers, they reflect a real gap in the safety data for this population.
What should you actually know?
BPC-157 is a synthetic peptide derived from a protein found in gastric juice. It has shown regenerative and anti-inflammatory effects in rodent and in vitro studies, but human clinical trial data remains extremely limited. The FDA has not approved BPC-157 for any indication, and compounded versions available through telehealth platforms are not equivalent to any approved drug product.
The cancer concern specifically comes down to one biological mechanism: angiogenesis. If a person has existing cancer cells, even micrometastatic disease they're not yet aware of, introducing a compound that promotes new blood vessel formation could theoretically provide those cells with the vascular infrastructure to grow. This is not science fiction. It is the same mechanism targeted by anti-angiogenic cancer drugs like bevacizumab. The concern is serious enough that major cancer centers advise against growth-factor-stimulating compounds during and after treatment.
- If you are currently in cancer treatment, do not use BPC-157 without explicit clearance from your oncologist.
- If you are in remission, the same applies. "Recently finished" is not a defined safe window.
- The creator's anecdotal evidence from their comments section is not clinical data and should not inform your decision.
- The absence of human trial data on cancer harm does not mean the risk has been studied and ruled out.